High‐performance Liquid Chromatographic Analysis of Pioglitazone, Gliquidone, Rosuvastatin and Simvastatin in Formulations and Human Serum

Abstract

Abstract Co‐administration of HMG‐CoA reductase with antidiabetic drugs is most common since antidiabetic drugs are mostly prescribed for long term therapy. In the present paper, we describe the simultaneous determination of antidiabetic (pioglitazone hydrochloride and gliquidone) in presence of statins (rosvastatin and simvastatin) in formulations and in human serum using RP‐HPLC technique. The serum samples were subjected to protein precipitation with acetonitrile prior to an HPLC analysis. At a flow rate of 1 mL·min −1 isocratic elution was employed, using mobile phase consisting of methanol/water (90:10, V : V ), pH 3.50 with phosphoric acid and absorbance was recorded at 235 nm. The assay was reproducible, linear (concentration range of 5–50 μg·mL −1 ) and accurate. The LOD and LOQ values were 1.32, 0.28, 0.05 and 0.57 μg·mL −1 and 4.39, 0.93, 0.16 and 1.90 μg·mL −1 for pioglitazone hydrochloride, gliquidone, rosvastatin and simvastatin, respectively. There were no interfering peaks due to the excipients present in the pharmaceutical tablet and serum. Thus, the proposed method is simple and suitable for the analysis of active ingredient in tablet form and human serum.